Is there a role for minimally invasive thermal ablations in the treatment of autonomously functioning thyroid nodules? by C.M. Pacella & G. Mauri
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=ihyt20
International Journal of Hyperthermia
ISSN: 0265-6736 (Print) 1464-5157 (Online) Journal homepage: https://www.tandfonline.com/loi/ihyt20
Is there a role for minimally invasive thermal
ablations in the treatment of autonomously
functioning thyroid nodules?
Claudio M. Pacella & Giovanni Mauri
To cite this article: Claudio M. Pacella & Giovanni Mauri (2018) Is there a role for minimally
invasive thermal ablations in the treatment of autonomously functioning thyroid nodules?,
International Journal of Hyperthermia, 34:5, 636-638, DOI: 10.1080/02656736.2018.1462537
To link to this article:  https://doi.org/10.1080/02656736.2018.1462537
Published online: 25 May 2018.
Submit your article to this journal 
Article views: 236
View related articles 
View Crossmark data
Citing articles: 2 View citing articles 
LETTER TO THE EDITOR
Is there a role for minimally invasive thermal ablations in the treatment of
autonomously functioning thyroid nodules?
Despite the explosive interest in US-guided thermal ablations
for percutaneous treatment of benign symptomatic thyroid
nodules, there is still no consensus for their use in function-
ing nodules. While the Korean Society of Radiology recom-
mended the use of radiofrequency ablation in 2012 for
‘patients with autonomously functioning thyroid nodules
(AFTN) causing problems related to thyrotoxicosis’ [1], the
recent update of the AACE-ACE-AME guidelines does not
include AFTN among the indications to thermal ablations [2].
AFTN account for up to 10% of cases of thyroid nodular
disease. Malignancy is extremely rare, surgery rarely neces-
sary, and radioiodine (131I) is considered as the first-line ther-
apy in the majority of patients, whether affected by
hyperthyroidism or not, and whether pre-treated with
antithyroid drugs or not [3–6]. Several studies have reported
normalization of thyroid function in 75–95% of patients
within 3–12months following 131I therapy, reduction of nod-
ule volume by 30–45% within 1–2 years and long-term
(5 years) risk of hypothyroidism of no more than 10–20%
[3,4,7]. Given that some patients might have contraindica-
tions to radiation exposure and that late hypothyroidism may
occur, minimally invasive therapies (MITs) have been used to
treat AFTN. Percutaneous ethanol injection (PEI), laser abla-
tion technique (LA) and radiofrequency ablation (RFA) have
been to be successful in the treatment of AFTN.
In a study by Monzani et al., 132 patients with AFTN were
treated with 2–16 PEI treatment sessions. The authors
reported that all 47 patients with pretoxic adenomas and 60
of the 85 patients (70.6%) with toxic adenomas were com-
pletely cured, while partial cure was observed in 11 cases
(12.9%), and failure in 14 (16.5%). Patients were followed for
up to 8.5 years (median 76months). However, with PEI treat-
ment, about 40 of the 132 patients reported mild to moder-
ate therapy-related pain [8]. Furthermore, in the case of
nodules with a high solid component, PEI has limited efficacy
due to the fact that ethanol does not easily diffuse into com-
pact tissue and therefore does not induce widespread, sus-
tained coagulative necrosis. Thus, this technique has now
been abandoned by most and it is only recommended as
first-line therapy in recurrent benign purely cystic nodules or
in those with a high cystic component.
The use of LA for AFTN has been tested in a few small ser-
ies of patients [9–17], with multiple LA sessions generally
needed to normalize serum TSH levels in solitary AFTN or in
multinodular goitres [11,13,16,17]. In a randomized trial, LA
and 131I treatments both resulted in a similar reduction of
AFTN volume but LA achieved normalization of serum TSH
levels in far fewer patients [14]. Similar outcomes were
obtained in some non-controlled series of AFTN treated with
RFA [18–23].
Some authors have reported that sustained, extensive
destruction of the functioning tissue is necessary to achieve
not only the improvement of symptoms but also their effect-
ive remission, with restored euthyroidism [17,24]. In their
2011 study [17], Amabile et al. reported excellent results
treating hyperfunctioning nodules with volumes exceeding
40ml by delivering a high amount of energy in multiple
treatment cycles (up to three) with multiple LA sessions (up
to three for each cycle). The serum FT3 levels of all 26
patients with hyperfunctioning thyroid nodules were normal-
ized, and in 23 of the 26 (88.5%) patients, a normalized
serum TSH level was observed. It seems important to note
that none of the patients developed hypothyroidism follow-
ing LA. The more favorable therapeutic outcome observed in
this series (88.5% of cured patients as compared to 50% in
the study by Dossing et al. [14]) is likely due to the different
mean percent reduction of nodular volume (77.3%) as com-
pared with 44% in the study by Dossing et al. [14]). ROC
curves identified the percentage of volume reduction as the
best parameter predicting a normalized serum TSH (area
under the curve 0.962; p< .0001). According to the ROC
curves, the cut-off of percent nodular volume reduction able
to guarantee the normalization of serum FT3 and TSH
was 79.3%.
The recent retrospective study by Gambelunghe et al. [25]
on 82 patients with three years of follow up published in the
February 2018 issue of IJH seems to confirm Amabile’s data.
Gambelunghe et al. conclude that it is possible to restore
euthyroidism when high percentages of coagulative necrosis
are obtained. These authors achieved a high percentage of
recovery in small nodules using a single treatment of LA;
results were progressively worse as nodule size increased.
Indeed, baseline nodule volume was significantly associated
with the treatment’s success; the percentage of patients who
discontinued methimazole therapy was inversely related with
the initial volume of the toxic nodules. All patients who had
nodules with a volume less than 5ml were able to suspend
methimazole, while 90.2% of patients with nodules with a
volume 5–15ml, 61.1% of those with a volume of 15–25ml
and 28.5% in nodules larger than 25ml suspended
the therapy.
Bernardi et al. also highlighted that a large reduction in
the volume of nodules treated with a single session was
important to restoring euthyroidism in hyperthyroid patients
[24]. In their study, the authors correlated volume reduction
at the twelfth month to therapeutic response. These authors
highlighted that a single RFA session reduced thyroid nodule
volume by 51%, 63%, 69% and 75% after 1, 3, 6 and
12months, respectively, and that a single RFA session
allowed 50% of the patients with AFTN to suspend
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antithyroid medication; these patients remained euthyroid
afterwards. The patients that went into complete symptom
remission had an average volume reduction of 81%, com-
pared to those patients that had only partial symptom
improvement, who had a 68% reduction.
In the January 2018 issue of IJH, Cesareo’s study [26] con-
firms these results obtained with a single session of RFA in
nodules with a volume 12ml. This was a 24-month pro-
spective monocentric open parallel-group trial in which 29
patients with AFTN were divided into 2 groups based on thy-
roid volume: 15 patients with small nodules (<12ml) in
group A and 14 patients with medium nodules (>12ml) in
group B. All patients were clinically, biochemically, and mor-
phologically evaluated at baseline and at 1, 6, 12 and
24months after treatment. After RFA, there was greater nod-
ule volume reduction in group A than in group B (p< .001
for each follow-up point). There was a greater increase in
TSH levels in group A than in group B at 6 (p¼ .01), 12
(p¼ .005) and 24months (p< .001). At 24months, the rate of
responders was greater in group A than in group B (86 vs
45%; p< .001). In group A, 86% of nodules converted from
hot to cold compared with 18% in group B (p< .001). The
authors thus conclude that a single session of RFA was
effective in restoring euthyroidism in patients with small
AFTN and state that nodule volume seems to be a significant
predictive factor of the efficacy of RFA in treating AFTN.
Thermal ablations can also be used in combination with
radioiodine ablation to accelerate the recovery process and
to reduce the radiation dose, as reported by Chianelli et al.
[27]. In their 24-month pilot prospective study in a popula-
tion of large toxic goiters (27.7 ± 17.0 vs 29.4 ± 10.6ml at
baseline), these investigators compared a group of 15
patients with functioning nodules treated with laser tech-
nique followed by radionuclide therapy (combined therapy)
with a group of 17 patients with matched clinical, demo-
graphic, and instrumental findings treated only with 131I.
Combined treatment determined faster control of hyperthy-
roidism. At 1month, normalization of TSH levels was
observed in the group treated with combined therapy. LA
resulted in a reduction in administered 131I activity (lower
than 600 MBq). In three patients with nodule size<5 cm, LA
induced normalization of TSH without any need for subse-
quent administration of radioiodine. Therefore, complete
ablation determines rapid recovery of thyroid function.
Finally, it should be emphasized that no patient in this series
progressed to hypothyroidism.
In conclusion, we think image-guided thermal ablations
might have a relevant application in the treatment of AFTN.
In this scenario, similarly than what happen in the treatment
of non-functioning thyroid nodules, LA and RFA seems to
provide similar clinical results [28–30]. Thus, more than the
used technique, the percentage of volume ablation seems to
play a crucial role in the treatment of AFTN with MITs. In
conclusion, in patients with nodules with volumes contained
around 13ml in which the functional and non-compressive
problem prevails, it is possible to solve the problem with a
single treatment in a high percentage of cases. In patients
with larger volume, thermal ablation can be used before
radioiodine ablation in order to fasten the recovery process
and to reduce the radiation dose to the patient.
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